#2024 Pan Pacific
The data herein supports the novel role of mutant CCR4 in enhancing T-cell lymphomagenesis and T-helper differentiation.
These highly encouraging data support further evaluation of epcoritamab.
NX-5948 showed tolerable safety and promising responses in patients with relapsed or refractory CLL or non-Hodgkin lymphoma.
Advertisement
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.